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Abstract 
BACKGROUND: Cancer is a major burden and threat to global society. A wide range of chemotherapeutic agents 
is extensively used to treat cancer at different stages. Inappropriate drug use may also lead to the raised cost of 
medical care, adverse drug effects, and patient mortality. Hence, in recent years, drug utilisation studies have 
become a potential tool to be used in the evaluation of different health care systems including cancer. 
AIMS: The objectives of the study were to identify the various types of cancer, the commonly prescribed drugs, 
rational use of anticancer drugs, and analyse the prescribing indicators in a tertiary care government hospital of 
India. 
MATERIAL AND METHODS: Newly diagnosed cancer and/or known case of carcinoma of either sex which 
required treatment/on treatment with chemotherapy aged > 18 yrs admitted in Radiotherapy Department from 
April 2016 to September 2016 were included in the study and analysed for prescribing indicators. 
RESULTS: The head & neck cancers were the prevalent cancers observed with more preponderance among 
males. Most of the patients were prescribed with a single anticancer drug. Cisplatin was the most commonly used 
cytotoxic drug followed by carboplatin, and antimetabolites. The most commonly used adjuvant drugs in our study 
were anti-emetics and anti-peptic ulcer drugs. Over 82% of anticancer agents were taken from the essential drug 
list and were prescribed in generic names, indicating rational use. 
CONCLUSION: Over 82% of anticancer agents were taken from the essential drug list and were prescribed in 
generic names, indicating rational use. 
 
 
 
 
 
 
 
Introduction 
 
Cancer is a major burden and threat to global 
society. It is one of the leading causes of death in both 
developed and developing countries [1]. A survey 
conducted by the World Health Organization (WHO) 
indicated that 8.2 million people succumbed from 
cancer in 2012, and it may rise to 19 million by 2025 
[2]. In India, the estimated number of people living 
with this disease is around 2.25 million, and the 
estimated numbers of new cancers are about 1.1 
million per year [3].
 
More than 0.6 million die because 
of cancer each year [3], and approximately 42% of 
cancers are tobacco related [4]. The main modalities 
used for its treatment include surgery, radiation, 
chemotherapy, immunotherapy, and hormones. The 
decision of therapy depends upon patient factors, 
tumour factors, and treatment factors [5]. A wide 
range of chemotherapeutic agents is extensively used 
to treat cancer at different stages. Chemotherapy 
refers to the usage of antineoplastic drugs to treat 
cancer as a standardised treatment regimen [6].
 
It is 
the only therapy which acts systematically to reduce 
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the disease from the entire body [5].
 
These drugs 
usually act on rapidly dividing cells and are either cell 
cycle specific or non-specific [7].
 
The drug use for the treatment of diseases is 
a complicated process since optimal benefits of drug 
therapeutics in patient care may not be obtained 
because of under-use, overuse or misuse of the 
drugs. Inappropriate drug use may also lead to the 
raised cost of medical care, adverse drug effects, and 
patient mortality. Hence, in recent years, DUS has 
become a potential tool to be used in the evaluation of 
different health care systems including cancer [8]. The 
evaluation of drug utilisation of anticancer drugs is 
necessary as their irrational use has generated a 
significant health problem in the current medical 
practice. Drug utilisation has been defined by the 
WHO as the marketing, distribution, prescription, and 
use of drugs in a society with specific emphasis on the 
resulting medical and social consequences [9]. Drug 
utilisation research promotes the rational use of drugs 
in the population [9]. Monitoring of drug utilisation 
patterns helps to improve the therapeutic efficacy, 
provides feedback to the prescriber to assure rational 
use of medicines and decrease the adverse drug 
reactions. The ultimate goal of drug utilisation 
research is to assess whether drug therapy is rational 
or not. Therefore, the present study aimed to analyse 
and evaluate the trends and patterns of prescribing 
anticancer drugs.  
The objectives of the study were to identify 
the various types of cancer, the commonly prescribed 
drugs, rational use of anticancer drugs, and analyse 
the prescribing indicators in a tertiary care 
government hospital of India. 
 
 
 
Material and Methods 
 
Study design  
The study was an observational, prospective, 
non-interventional study 
 
Study site  
The study was conducted in the cancer 
radiotherapy department of Vijayanagara Institute of 
Medical Sciences, Ballari, one of the major 
government tertiary care hospitals for cancer 
treatment near the Hyderabad- Karnataka region. The 
study was performed after receiving the necessary 
ethical clearance from the Institutional Ethics 
Committee. 
 
 
Study Duration 
It was carried out for six months, period from 
April 2016 to September 2016 
 
Inclusion criteria  
Newly diagnosed cancer &/or known case of 
carcinoma of either sex which required treatment/on 
treatment with chemotherapy aged > 18yrs admitted 
in the Radiotherapy Department from April 2016 to 
September 2016 was included in the study. The 
written informed consent was taken before the start of 
the study. All the patients were observed for the 
complete duration of the study.  
 
Exclusion criteria  
Patients who were pregnant or having 
insufficient records and data were excluded from the 
study. 
 
Sample size calculation 
The sample size was designed based on the 
average number of inpatients admitted and registered 
in the earlier six months of the study period. A total 
number of 144 patients were recruited in the study 
from April 2016 to September 2016. 
 
Data collection 
Data were collected and entered in specially 
designed patient data entry forms. The prescription 
parameters needed for the study were recorded. 
 
Data analysis 
The data were entered in Microsoft Excel 
(Windows 7; Version 2007). The collected data of 
demographic and clinical variables were analysed 
using descriptive statistics such as frequencies and 
percentage, were represented in tables and figures. 
WHO core prescribing indicators was compiled at the 
end of the study to know the number of prescriptions 
with polypharmacy, per cent of prescriptions with 
injectables, per cent of drugs prescribed from 
Essential Drugs list.  
 
 
Results  
 
Age 
The majority of patients (36.8%) were in the 
age group of 56-65 years followed by 18.05% in 46-55 
years (26 patients), 17.36% > 65 years (25 patients), 
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14.58% in 36-45 years (21 patients), 9.02% in 26-35 
years (13 patients) and 4.16% in 18-25 years (6 
patients). The mean age of the participants was found 
to be 53.86 years. 
 
Sex  
Males constituted 54.86% (79 patients), and 
females constituted 45.13% (65 patients) of the total 
study population.  
 
Distribution of cancer 
Table 1, shows the system-wide distribution of 
cancer among study participants. The head and neck 
cancers were more predominant (46.7%), followed by 
gastrointestinal cancer (24.1%), reproductive system 
(14.51%), breast (11.29%) and respiratory cancers 
(3.22%). 
Table 1: System-wise distribution of cancers 
Organ System name % pts 
Gastrointestinal 24.1 
Head and neck cancers 46.52 
Breast cancers 11.29 
Reproductive system 14.51 
Respiratory 3.22 
 
 
The organ-wise distribution is shown in Figure 
1.  
 
Figure 1: Organ-wise distribution of the cancers 
 
Drug utilisation pattern: Out of 144 cancer 
patients analysed, 65.27% patients (94) was 
prescribed with single anticancer drug therapy while 
the remaining patients were given multiple anticancer 
drugs therapy.  
The treatment regimens used in different 
organ system cancer is shown in Table 2. 
 
 
 
Table 2: The different treatment regimens used in cancer 
patients 
Organ System name % pts Treatment regimens used 
Gastrointestinal 24.1 1. Cisplatin/Carboplatin + Radiation therapy 
2.Oxaliplatin+Capacetabine 
3. 5-FU(5-Fluorouracil) + Radiation therapy 
4.5FU + Oxaliplatin(FOLFOX) 
5. DCF-docetaxel, cisplatin + 5-fluorouracil 
6. GEMOX- Gemcitabine + oxaliplatin 
Head and neck cancers 46.52 1.Cisplatin/Carboplatin (+ o r-) Radiation 
therapy 
2.Cisplatin+ Paclitaxel (+or-) Radiation 
Therapy 
 
Breast cancers 11.29 1.Doxorubicin+Cyclophosphamide+Radiation 
Therapy 
2. Paclitaxel 
Reproductive system 14.51 1. Cisplatin+ Radiation therapy 
2. Carboplatin+ Paclitaxel 
Respiratory 3.22 Carboplatin+ Paclitaxel 
 
The anticancer drugs, the adjuvant drugs and 
other supportive drugs pattern is depicted in Figures 
2, 3 and Tables 3, 4 and 5. 
 
Figure 2: Anticancer class- wise usage of the drugs 
 
 
Discussion 
 
Anticancer drugs utilisation 
Totally 184 anticancer drugs were given to 
144 study participants. The average number of these 
drugs in our study was 1.27 per patient. The present 
research showed that the most common class of 
cytotoxic agents prescribed was platinum compounds 
(64.58%).  
Table 3: Prescription pattern of each anticancer drug 
Name of Anticancer drug Number of pts prescribed(n) (%) 
5-Fluorouracil 16 8.7 
Capecitabine 13 7.07 
Carboplatin 38 20.65 
Cisplatin 45 24.46 
Cyclophosphamide 18 9.78 
Docetaxel 8 4.35 
Doxorubicin 11 5.98 
Gemcitabine 8 4.35 
Oxaliplatin 10 5.43 
Paclitaxel 17 9.24 
 184 100 
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Amongst the platinum analogues, the most 
commonly used drug was cisplatin that comprised 
24.46%, followed by carboplatin and oxaliplatin which 
formed 20.65% and 5.43% respectively of all 
anticancer drugs. Cisplatin was used with 
radiotherapy in 33.3% of patients for the management 
of carcinoma of tongue, cervix, oesophagus and 
hypopharynx which were the most common types of 
cancers in the study population.  
 
Figure 3: Drug class-wise usage of adjuvant & supportive drugs 
 
Carboplatin with radiotherapy was the second 
common standard regimen in cancer of the tongue 
and oral cavity in the present study. The 
antimetabolites were the next commonly prescribed 
anticancer drug class accounting for 25.69% of all 
anticancer drugs. 5-Fluorouracil was most common 
antimetabolite given (43.24%).  
Table 4: Prescription pattern of each adjuvant drug 
Drug name Number of pts given (%) 
 
Aprepitant 4 0.586 
Dexamethasone 131 19.2 
Furosemide 63 9.23 
Potassium Chloride 67 9.82 
Leucovorin 3 0.439 
MESNA 4 0.586 
Magnesium sulphate 69 10.11 
Ondansetron 143 20.96 
Pantaprozole 60 8.79 
Rantac 82 12.01 
Chlorpheniramine 8 1.17 
 
The other antimetabolites used were 
capecitabine (35.13%) and gemcitabine (21.6%). 
They were used in gastrointestinal cancers like 
carcinoma of rectum, colon and stomach. The use of 
cisplatin (18.5 %) and 5-FU (13 %) were also higher in 
a comparable study conducted by Dave et al., at PDU 
Govt. Medical College and Hospital, Gujarat [10]. 
Similar findings were seen in other related studies of 
Mary Rohini et al., 2015, Goyal et al., 2014 and 
Darshan et al., 2014 [11], [12], [13].
 
Table 5: Prescription pattern of other supportive drugs 
Drug name Number of pts given (%) 
Multivitamin injection 41 6.01 
Sucracure 3 0.439 
Zoledronic acid 4 0.586 
Total- Adjuvant & other 
supportive drugs 
682 100 
 
After antimetabolites, taxanes and alkylating 
agents were the 3rd and 4th commonest class of 
agents used. Amongst the taxanes which accounted 
for 17.36% anticancer drug use, the commonest 
taxane used was paclitaxel (68%), followed by 
docetaxel (32%). They were prescribed in carcinoma 
of the breast with secondaries, cervix, lung and 
stomach.  
 
Adjuvant and supportive drugs utilisation 
pattern 
Cancer chemotherapy includes anticancer 
medicines accompanied by adjuvant and 
supplementing therapeutic measures. These 
additional medications other than the anti-neoplastic 
drugs are used for reducing the adverse effects seen 
with the cancer chemotherapy. In total, 682 adjuvant 
drugs were given to 144 study participants. The 
average number of these drugs in our study were 4.73 
per patient. The prescribing pattern of the different 
adjuvant and supportive drugs used is shown in Table 
4 and 5. The antiemetics were the most commonly 
prescribed pre-chemotherapy drug accounted for 
21.54% of total adjuvant drugs given, followed by the 
drugs used to reduce gastric acidity which constituted 
20.8%. Inj Ondansetron was the most common used 
antiemetic dug which was administered intravenously 
in almost all patients, and Aprepitant was used in only 
in 4 patients of the study. On an average 90.9% of the 
patients were prescribed dexamethasone along with 
the chemotherapy. This adjuvant steroid, when used 
with chemotherapy, minimises the adverse effects like 
nausea and vomiting caused by chemotherapy 
medications. Also, it has found to improve appetite, 
decrease inflammation at the cancer site, and also 
decrease the elevated blood calcium levels (which is 
connected with some bone cancer cases) [14].
 
Cisplatin/carboplatin-based chemotherapy 
regimen causes hypomagnesemia and hypokalemia 
due to renal magnesium (Mg) and potassium (K) 
losses. Therefore potassium chloride and magnesium 
sulphate were given to almost all the patients 
receiving a cisplatin/carboplatin-based chemotherapy 
regimen. These patients also have a high risk of renal 
tubular dysfunction and a cumulative impairment in 
renal function, manifested by a decline in the 
glomerular filtration rate [15]. To prevent the 
development of nephrotoxicity, forced hydration in the 
form of saline infusion before, on the day of 
chemotherapy, and following cisplatin [16] and 
diuresis, by furosemide was given to the patients in 
our study. Although some researchers have already 
reported the effect of furosemide on reducing the 
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renal toxicity, its effect on the prevention of 
nephrotoxicity is still controversial [17].
 
It has been 
reported that furosemide protects renal function, while 
it worsens renal histopathology [18]. However, it is 
discovered that prophylactic magnesium 
supplementation, in addition to curbing adverse 
effects that occur directly from magnesium deficiency, 
can minimise the severity of cisplatin-induced renal 
damage without interfering with the anticancer effect 
of the drug [19].
 
Magnesium performs an essential 
role in the preservation of intracellular K
+
 loss too. 
Therefore, in the present study, furosemide was 
always co-prescribed with MgSO4 to reduce the 
nephrotoxicity of cisplatin. 
 CPM was used as an antiallergic among 
eight patients. Chlorpheniramine maleate has found to 
be effective, patient convenient and very useful in 
preventing allergic reaction due to paclitaxel [20]. 
Mesna was used along with cyclophosphamide to 
prevent hemorrhagic cystitis. The other drugs 
prescribed included zoledronic acid in breast cancer 
with secondaries in bones. Administration of 
anticancer drugs is associated in some patients with 
severe acid reflux diseases which require the 
prescription of proton pump inhibitors, H2 antagonist 
and antacid prophylactically as well as therapeutically 
to the patients [21]. In our study, as gastric 
protectants, Ranitidine or Pantaprozole were given 
intravenously. Inj Ranitidine formed 12.01%, followed 
by Inj Pantaprozole which was 8.79% of the total 
prechemotherapy drugs in all the study groups. Inj 
Ranitidine was given in 82 patients and Inj 
Pantaprozole in 60 patients. 
Table 6: WHO prescribing indicators 
Prescribing Indicators In patients 
Number of drugs prescribed per patient 6.01 
Percentage of drugs prescribed by Generic 
name 
76.7% 
Number of anti-cancer drugs prescribed per 
patient 
1.27 
Number of adjuvant/supportive drugs 
prescribed per patient 
4.73 
Percentage of drugs prescribed from 
national essential drug list 
82.2% 
 
The prescribing indicator shows that the 
average number of cytotoxic drugs per prescription 
was 1.277, which was near to study conducted by B. 
Sajeev Kumar et al., (1.73) [22] and relatively lower 
than that of comparable studies conducted in Brazil 
(2.4), Jordan (2.3) and in other places in India (2.7) 
[23]. The average number of drugs per prescript was 
6.01. The number of adjuvant/supportive drugs 
prescribed per patient was 4.73. The percentage of 
drugs prescribed by the Essential Drug List was 82%. 
The drugs were prescribed based on the hospital 
formulary and supplied on a nonprofit basis by the 
government. The percentage of drugs ordered by the 
generic name was 77%. Prescribing medicines by 
generic name must be strengthened since generic 
medicines are as efficient as brand ones, and they 
cost less which lowers the medical expenditure. 
In conclusion, the head & neck cancers were 
the prevalent cancers observed with more 
preponderance among males. Most of the patients 
were prescribed with a single anticancer drug. 
Cisplatin was the most commonly used cytotoxic drug 
followed by carboplatin, and antimetabolites. The 
most commonly used adjuvant drugs in our study 
were anti-emetics and anti-peptic ulcer drugs. Over 
82% of anticancer agents were taken from the 
essential drug list and were prescribed in generic 
names, indicating rational use. WHO promotes that 
more such drug utilisation studies are needed in every 
health care setting to assess and assure the rational 
drug use. 
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